Future of Drug Discovery

In this episode of Future of Drug Discovery, we speak with Louise Liu, Founder and CEO of Hill Research. 

The statistical programming behind an FDA submission is one of the slower steps in clinical development. Eight programmers, six months and eight million dollars is roughly what it takes to produce the data package for a single Phase 3 trial.

Hill Research is doing that work with one person, in 90 minutes, with the help of generative AI. 

In this conversation, we get into how the technology works, what the FDA thinks about the use of AI in submissions, the accountability question pharma executives are asking, and what the next decade of clinical development could look like if the rest of the pipeline catches up.

Be sure to like, rate and review the podcast if you enjoyed this episode! 

Links:

Hill Research: https://www.hillresearch.ai/

Louise’s LinkedIn: https://www.linkedin.com/in/louise-liu-phd-mba-hill-research/

Visit our website: ⁠https://www.antiverse.io/⁠

Follow Antiverse: 

LinkedIn: ⁠⁠⁠⁠https://www.linkedin.com/company/antiverse/⁠⁠⁠⁠⁠⁠⁠⁠ 

X: ⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/AntiverseHQ⁠⁠

This episode is a discussion between ⁠Rahmad Akbar, Senior Data Scientist in Antibody Design at Novo Nordisk and Murat Tunaboylu⁠, Co-Founder and CEO of Antiverse⁠.

You will learn:

Rahmad's LinkedIn page.

Rahmad's Personal Website.

Antibody Origami: Here.

Rahmad's Previous and Existing Team: Victor Greiff (GreiffLab). Paolo Marcatili, Ludovica Beltrame, Rasmus Høiberg-Nielsen (Antibody Design at Novo Nordisk).

"And a big shout out to budding antibody designers (scientists) everywhere especially from my home country Indonesia!' - Rahmad.

This episode is a discussion between Paul Essery, Host of 'The Tech Business Podcast' and Murat Tunaboylu Co-Founder and CEO of Antiverse.

You will learn:

Be sure to like, rate and/or review the podcast if you enjoyed it!

Visit our website: https://www.antiverse.io/

Follow us:

LinkedIn: ⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/antiverse/⁠⁠⁠⁠⁠⁠

X: ⁠⁠⁠⁠⁠⁠https://twitter.com/AntiverseHQ⁠⁠

In this episode, we speak with ⁠⁠Björn Schimmöller, Co-Founder and CEO of iuvantium, a synthetic immunobiology company developing new modalities for the next generation of immunotherapies.

Host: ⁠⁠Murat Tunaboylu⁠⁠, Co-Founder and CEO of Antiverse.

You will learn:

• The founding journey of iuvantium from Oxford University.
• How Iuvantium is enhancing immune system efficiency and reducing clinical trial uncertainty using inorganic chemistry.
• ‘Decoding’ the immune system and how personalised medicine may lead to the next leaps in immunotherapy.

Things mentioned:

• ⁠⁠AstraZeneca COVID-19 vaccine
• John Austyn - CSO and Co-Founder of Iuvantium
• Ralph Steinman
• Farooq Khan - AI Architect at Iuvantium
• ‘Artificial Lymph Nodes’
• Simon Sinek - The Infinite Game

Additional Materials:

• ⁠Contact iuvantium: [email protected]⁠⁠
• iuvantium website: https://iuvantium.com/
• iuvantium LinkedIn: https://www.linkedin.com/company/iuvantium/

First time hearing about Antiverse?

Antiverse is an artificial intelligence-driven techbio company that specialises in antibody design against difficult-to-drug targets, including G-protein coupled receptors (GPCRs) and ion channels. Headquartered in Cardiff, UK and with offices in Boston, MA, Antiverse combines state-of-the-art machine learning techniques and advanced cell line engineering to develop de novo antibody therapeutics. With a primary focus on establishing long-term partnerships, Antiverse has collaborated with two top 20 global pharmaceutical companies. In addition, they are developing a strong internal pipeline of antibodies against several challenging drug targets across various indications.

For more information, please visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.antiverse.io⁠⁠

Never miss a future event!

We'll notify you when a new event is scheduled. Fill out ⁠⁠⁠⁠⁠⁠this form⁠⁠⁠⁠⁠⁠ to sign up for marketing communications from Antiverse. We post about upcoming events on LinkedIn and Twitter.

LinkedIn: ⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/antiverse/⁠⁠⁠⁠⁠⁠

X: ⁠⁠⁠⁠⁠⁠https://twitter.com/AntiverseHQ⁠⁠

In this episode, we speak with ⁠Ashwini Ghogare⁠, Head of Artificial Intelligence and Automation in Drug Discovery at ⁠MilliporeSigma⁠, the Global Science and Technology Group at ⁠Merck⁠.

Host: ⁠Murat Tunaboylu⁠, Co-Founder and CEO of Antiverse.

You will learn:

• About Ashwini’s journey to her current role.
• How to bridge the gaps between working groups with different skill sets for optimal computational drug discovery.
• The interplay between AIDDISON™ and SYNTHIA™ to automate the drug discovery process.
• The industry's critical requirements for progress in the AI drug discovery space.

Things mentioned:

• ⁠MELLODDY⁠
• ⁠AIDDISON™: Harnessing Generative AI to Revolutionize Drug Discovery⁠⁠⁠
• ⁠SYNTHIA™: Our Retrosynthsis Software Can Save Years of Research⁠

Additional Materials:

• ⁠⁠AIDDISON™ Drug Discovery Platform ⁠Product page.
• ⁠⁠Future Talk: Discovering Drugs with AI-Powered Tools⁠⁠ Merck Podcast, ft. Ashwini.
• ⁠⁠Davos: Impacting Life & Health with Science & Tech⁠⁠: Merck - Impacting Life & Health With Science & Tech (Video)
• ⁠⁠C&EN: Hunting for Drugs in Chemical Space⁠⁠ Article on AI Drug Discovery.

First time hearing about Antiverse?

Antiverse is an artificial intelligence-driven techbio company that specialises in antibody design against difficult-to-drug targets, including G-protein coupled receptors (GPCRs) and ion channels. Headquartered in Cardiff, UK and with offices in Boston, MA, Antiverse combines state-of-the-art machine learning techniques and advanced cell line engineering to develop de novo antibody therapeutics. With a primary focus on establishing long-term partnerships, Antiverse has collaborated with two top 20 global pharmaceutical companies. In addition, they are developing a strong internal pipeline of antibodies against several challenging drug targets across various indications.

For more information, please visit ⁠⁠⁠⁠⁠⁠https://www.antiverse.io⁠

Never miss a future event!

We'll notify you when a new event is scheduled. Fill out ⁠⁠⁠⁠⁠this form⁠⁠⁠⁠⁠ to sign up for marketing communications from Antiverse. We post about upcoming events on LinkedIn and Twitter.

LinkedIn: ⁠⁠⁠⁠⁠https://www.linkedin.com/company/antiverse/⁠⁠⁠⁠⁠

X: ⁠⁠⁠⁠⁠https://twitter.com/AntiverseHQ⁠⁠

In this talk, Murat speaks with Ming (Tommy) Tang, Director of Computational Biology at Immunitas Therapeutics, an immuno-oncology start-up developing novel therapeutics for patients with cancer. 

Tommy is a strong leader and communicator in the field of computational biology. He has dedicated his life's work to accelerating cancer research, with prominent expertise in analysing large-scale bulk sequencing data, single-cell and spatial transcriptomic data and epigenetic data.

Outside of his career at Immunitas, Tommy is a brilliant science communicator and teacher, with various educational streams, including Twitter, a blog, a GitHub repository, a YouTube channel, a newsletter, as well as authoring his own book, 'From Cell Line To Command Line'. He is passionate about teaching biologists the computational skills essential for modern science. 

You will learn:

• How to stay ahead of the curve: developing the data analysis and bioinformatics skills essential to modern research.
• How Immunitas is developing a discovery engine to aid the fight against cancer and the computational workflows behind it.
• How to transition from a biologist to a computational biologist.
• About the shift from academia to industry.
• About Tommy's inspiring journey.

Things mentioned:

Link to all Tommy's resources: https://tommytang.bio.link/

• Shanghai Jiao Tong University
• University of Florida
• MOOC Platforms: Udacity, Coursera, edX
• Biostars
• MD Anderson Cancer Center
• Roel Verhaak
  
• Cancer Genome Atlas Project
• Harvard Faculty of Arts and Sciences
• Shirley Liu's group at Dana Farber
• Cancer Immunological Data Commons
• Mount Sinai
• Stanford
• Tommy's Blog: https://divingintogeneticsandgenomics.com/
• Immunitas's lead candidate: CD161 / IMT-009 / KORV1
• Workflow management systems: SnakeMake, Nextflow...
• Visgene
• Matthew Berstein
• PD-1
• Recursion Bridges the Protein and Chemical Space with Massive Protein-Ligand Interaction Predictions Spanning 36 Billion Compounds.

Additional Materials: 

• ⁠⁠⁠⁠⁠⁠⁠⁠⁠Watch the recording of the live event! ⁠https://youtu.be/CYa9rDFDaaI

First time hearing about Antiverse?

Antiverse is an artificial intelligence-driven techbio company that specialises in antibody design against difficult-to-drug targets, including G-protein coupled receptors (GPCRs) and ion channels. Headquartered in Cardiff, UK and with offices in Boston, MA, Antiverse combines state-of-the-art machine learning techniques and advanced cell line engineering to develop de novo antibody therapeutics. With a main focus on establishing long-term partnerships, Antiverse has collaborated with two top 20 global pharmaceutical companies. In addition, they are developing a strong internal pipeline of antibodies against several challenging drug targets across various indications.

For more information, please visit ⁠⁠https://www.antiverse.io⁠⁠

Never miss a future event!

We'll notify you when there's a new event scheduled. Fill out ⁠⁠⁠this form⁠⁠⁠ to sign up for marketing communications from Antiverse. We post about upcoming events on LinkedIn and Twitter.

LinkedIn: ⁠⁠⁠https://www.linkedin.com/company/antiverse/⁠⁠⁠

X: ⁠⁠⁠https://twitter.com/AntiverseHQ⁠

In this talk, Murat speaks with ⁠Nikhil Podduturi⁠, Head of Data Science at the Digital Lab of ⁠Boehringer Ingelheim⁠ - ⁠(BI X)⁠.  

Nikhil co-leads the laboratory and data science chapters at the BI X headquarters in Germany and China. The team at BI X is pioneering digital innovations to improve the lives of patients and animals. The current technologies developed by BI X include PetPro Connect, Farmera, and Pathological Speech Processing, with impacts spanning multiple healthcare fields. 

Nikhil's current work involves developing new tools to accelerate drug discovery with advanced genetic sequencing technologies, designing new in silico systems to identify indications for drugs, as well as incorporating AI and ML technologies across BI X's digital health platforms. 

You will learn:

• How the BI X team was founded.
• How BI X is using a data-driven approach to advance drug discovery and healthcare.   
• Regulatory steps involved in approving a digital health product.
• Future directions for BI X.
• How to get involved.

Things mentioned:

• Center for Computational Biology and Bioinformatics at Columbia
• Mike Schmelmer
• Alibaba
• Oxford Nanopore
• SAMD - Software as a Medical Device
• ISO - International Organization for Standardisation
• ESMFold: Read here
• UK Biobank

Additional Materials: 

• ⁠⁠⁠⁠⁠⁠⁠Watch the recording of the live event! https://youtu.be/5l69jvIu5DQ

First time hearing about Antiverse?

Antiverse is an artificial intelligence-driven techbio company that specialises in antibody design against difficult-to-drug targets, including G-protein coupled receptors (GPCRs) and ion channels. Headquartered in Cardiff, UK and with offices in Boston, MA, Antiverse combines state-of-the-art machine learning techniques and advanced cell line engineering to develop de novo antibody therapeutics. With a main focus on establishing long-term partnerships, Antiverse has collaborated with two top 20 global pharmaceutical companies. In addition, they are developing a strong internal pipeline of antibodies against several challenging drug targets across various indications.

For more information, please visit ⁠https://www.antiverse.io⁠

Never miss a future event!

We'll notify you when there's a new event scheduled. Fill out ⁠⁠this form⁠⁠ to sign up for marketing communications from Antiverse. We post about upcoming events on LinkedIn and Twitter.

LinkedIn: ⁠⁠https://www.linkedin.com/company/antiverse/⁠⁠

X: ⁠⁠https://twitter.com/AntiverseHQ⁠

In this talk, Murat speaks with Abhishek Pandey, Principle Research Scientist and Pharma Discovery Group Lead at AbbVie. 

Abhishek currently leads RAIDERS, a Pharma Discovery group integrating machine learning across all of AbbVie's working groups to augment drug discovery capabilities. Abhishek's groups work spans cheminformatics, imaging research, multi-omics, as well as the computation behind many of AbbVie's current partnerships and collaborations. 

We'll be exploring how the machine learning group is transforming the processes across multiple working groups at the pharmaceutical giant, AbbVie. We'll also be unravelling the story of how Abhishek began his pioneering work at AbbVie.

You will learn:

• About Abhishek's strategy for bridging chemistry, biology and computer science expertise to integrate machine learning across AbbVie's pharma discovery processes.
• About Abhishek's vision for the future of drug discovery, as we explore the pressing needs of the pharmaceutical industry from both a technical and social standpoint.

About Abhishek:

Abhishek started his career as a software engineer at Toshiba. Following this, Abhishek began his PhD in medical engineering and image processing at the University of Arizona. This led Abhishek to become a core member of the precision medicine AI team at Tempus, developing ways to improve cancer imaging pipelines to help oncologists detect cancers more efficiently. Abhishek then joined AbbVie, where he founded the machine learning / deep learning team - the influence of which has expanded across the entire company. 

Things mentioned:

• Abhishek Pandey⁠, Principle Research Scientist and Pharma Discovery Group Lead at ⁠AbbVie⁠.
• RAIDERS: Pharma Discovery and Developmental Sciences team at AbbVie.
• Google
• Meta
• Toshiba
• Tempus Labs (now Tempus).
• PADME (Protein And Drug Molecule interaction prEdiction), a framework based on Deep Neural Networks, to predict real-valued interaction strength between compounds and proteins.
• NeurIPS Conference (Conference on Neural Information Processing Systems)
• InSitro
• Facebook

Additional Materials: 

• ⁠⁠⁠⁠⁠Watch the recording of the live event! ⁠https://www.youtube.com/watch?v=F9kADawRPOs

First time hearing about Antiverse?

Antiverse is an artificial intelligence-driven techbio company that specialises in antibody design against difficult-to-drug targets, including G-protein coupled receptors (GPCRs) and ion channels. Headquartered in Cardiff, UK and with offices in Boston, MA, Antiverse combines state-of-the-art machine learning techniques and advanced cell line engineering to develop de novo antibody therapeutics. With a main focus on establishing long-term partnerships, Antiverse has collaborated with two top 20 global pharmaceutical companies. In addition, they are developing a strong internal pipeline of antibodies against several challenging drug targets across various indications.

For more information, please visit https://www.antiverse.io

Never miss a future event!

We'll notify you when there's a new event scheduled. Fill out ⁠this form⁠ to sign up for marketing communications from Antiverse. We post about upcoming events on LinkedIn and Twitter.

LinkedIn: ⁠https://www.linkedin.com/company/antiverse/⁠

Twitter (x.com) : ⁠https://twitter.com/AntiverseHQ

In this talk, Murat speaks with Tzvika Hartman, Senior Vice President of Computation at Biolojic Design, a company curating AI-designed antibodies focused on autoimmune diseases and immuno-oncology applications. 

Biolojic uses machine learning to design 'programmable' antibodies with more precise molecular effects. These antibodies work dynamically with their environment, both temporally and spatially, opening avenues for new ways to alter biology. Their lead candidate, AU-007, pioneered by spin-out company Aulos Bioscience, is being advanced through Phase II clinical studies in solid tumour cancers. 

Don't miss this exciting opportunity to learn about the technology and strategies at Biolojic Design directly from Tzvika. Furthermore, we'll be exploring Tzvika's fascinating and eventful career. 

About Tzvika:

Tzvika has more than 30 years of experience in computer science research and software engineering. He worked at Google, Tel Aviv for 8 years as a software engineer, before founding Google's Health group in Tel Aviv, leading various projects over 5 years. Tzvika now leads the computational advancements at Biolojic Design. 
Things mentioned:

• ⁠⁠⁠Tzvika Hartman⁠, Senior Vice President of Computation at ⁠Biolojic Design⁠.
• Weitzman Institute
• Google, Tel Aviv
• Google Trends
• 'Multibodies', Biolojic's proprietary antibody format.
• ChatGPT
• Novartis
• Eli Lilly
• AstraZeneca
• AU-007, selective effector cells agonist for IO - Anti-IL2 epitope-specific antibody.

Additional Materials: 

• ⁠⁠⁠Watch the recording of the live event! https://youtu.be/XKJFFcFMt5c?feature=shared

About Antiverse:

Antiverse was co-founded in 2017 with the goal of engineering the future of drug discovery to change people's lives. Based in Cardiff, Antiverse combines machine learning and phage display techniques to model antibody-antigen interactions. The current version of the platform uses next-generation sequencing and AI to design diverse antibody candidates for any given target. The technology is being developed to enable the discovery of biologics for difficult-to-drug targets associated with cancer, heart, and lung diseases.

Never miss a future event!

We'll notify you when there's a new event scheduled. Fill out this form to sign up for marketing communications from Antiverse. We post about upcoming events on LinkedIn and Twitter.

LinkedIn: https://www.linkedin.com/company/antiverse/

Twitter (x.com) : https://twitter.com/AntiverseHQ

In this captivating podcast series, we dive deep into the world of computational antibody discovery with Ben Holland, our Co-Founder and CTO at Antiverse⁠. Join us as we uncover the immense potential of merging computational and experimental techniques in the pursuit of revolutionary antibodies, as Ben sheds light on the strong benefits and formidable challenges encountered when targeting complex molecules such as GPCRs. With an emphasis on precision and accuracy in predicting antibody-antigen interactions, Ben shares remarkable insights and breakthroughs achieved by computational discovery techniques. Tune in and join us at the forefront of antibody discovery!

Things mentioned:

• ⁠⁠Ben Holland, Co-Founder and CEO of Antiverse.

• ⁠⁠⁠⁠Antiverse⁠, an AI-first biologics discovery company that designs antibodies against difficult -to-drug targets.

• Watch the full presentation, with slides! https://youtu.be/v8-ZrR7L83s

• Watch the full Computational Antibody Discovery Symposium, hosted by The Antibody Society, NaturalAntibody and AstraZeneca! https://youtube.com/playlist?list=PLWG3bWQmCPkPPfDhqiRqKWmqHYumJXlHq

Additional Materials: 

• ⁠⁠⁠Contact us about your discovery projects by emailing ⁠[email protected]⁠.

About Antiverse:

Antiverse was co-founded in 2017 with the goal of engineering the future of drug discovery to change people's lives. Based in Cardiff, Antiverse combines machine learning and phage display techniques to model antibody-antigen interactions. The current version of the platform uses next-generation sequencing and AI to design diverse antibody candidates for any given target. The technology is being developed to enable the discovery of biologics for difficult-to-drug targets associated with cancer, heart, and lung diseases.